AsianScientist (Jul. 6, 2016) – Takeda Pharmaceutical Company Limited and Altos Therapeutics LLC have entered into a partnership to further the development of Altos’s proprietary compound ATC-1906.
Headquartered in Los Altos, California, Altos is a single asset pharmaceutical company whose main focus has been to develop ATC-1906 for gastroparesis (GP). The agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing Phase I studies of ATC-1906.
GP is a chronic gastric motility disorder characterized by delayed gastric emptying. In patients with GP, the activation of dopamine receptors drives an emetic response commonly known as vomiting. Symptoms include early satiety, post-meal fullness, nausea, vomiting and abdominal discomfort. ATC-1906 compound is an oral dopamine D2/D3 receptor antagonist that addresses the symptoms of nausea and vomiting in GP patients.
As part of the agreement, Takeda will provide Altos an upfront payment for the option to acquire Altos. If Takeda elects to exercise the option, Takeda would make an additional payment to acquire Altos, and would then assume control over development and commercialization of ATC-1906. Altos would be eligible to receive additional payments linked to clinical development and achievement of key commercial milestones.
“There is a significant unmet need for a treatment to help patients with gastroparesis, and developing novel and innovative treatments for patients suffering from gastrointestinal disorders is a top priority for Takeda’s global R&D strategy,” said Dr. Asit Parikh, senior vice president and head of Takeda’s Gastroenterology Therapeutic Area Unit.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.